Skip to main content

Table 3 Univariable analyses of PFS and OS

From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Variables

PFS

OS

HR

95% CI

p value

HR

95% CI

p value

Age (years)

  

0.015*

  

0.008**

  ≤ 65

Ref.

  

Ref.

  

 >65

1.567

1.093–2.248

 

1.666

1.142–2.429

 

Sex

  

0.174

  

0.365

 Male

1.320

0.885–1.968

 

1.216

0.796–1.859

 

 Female

Ref.

  

Ref.

  

Smoking

  

0.391

  

0.717

 Never

Ref.

  

Ref.

  

 Ever

1.168

0.819–1.665

 

1.070

0.741–1.547

 

ECOG PS

  

0.007**

  

0.019*

 0

Ref.

  

Ref.

  

 1

1.610

1.136–2.283

 

1.548

1.073–2.234

 

Lesion type

  

0.086

  

0.443

 Peripheral

Ref.

  

Ref.

  

 Central

1.357

0.958–1.922

 

1.152

0.802–1.655

 

Histological type

  

0.835

  

0.816

 Adenocarcinoma

Ref.

  

Ref.

  

 Squamous

1.038

0.728–1.482

 

0.957

0.661–1.386

 

Clinical stage

  

0.017*

  

0.045*

 IIIB

Ref.

  

Ref.

  

 IV

1.529

1.078–2.168

 

1.450

1.008–2.086

 

First-line response

  

< 0.001***

  

< 0.001***

 CR/PR

Ref.

  

Ref.

  

 SD/PD

2.725

1.905–3.898

 

2.966

2.044–4.306

 

CEA

  

0.280

  

0.719

 Normal

1.219

0.851–1.746

 

1.071

0.737–1.557

 

 Increased

Ref.

  

Ref.

  

Albumin

  

0.023*

  

0.140

 Decreased

1.521

1.059–2.183

 

1.323

0.913–1.918

 

 Normal

Ref.

  

Ref.

  

WBC

  

0.098

  

0.158

  ≤ 7.8

Ref.

  

Ref.

  

 >7.8

1.337

0.948–1.887

 

1.297

0.904–1.860

 

LMR

  

< 0.001***

  

< 0.001***

  ≤ 3.73

2.373

1.643–3.429

 

2.437

1.659–3.579

 

 >3.73

Ref.

  

Ref.

  

NLR

  

0.064

  

0.067

  ≤ 2.67

Ref.

  

Ref.

  

 >2.67

1.395

0.981–1.984

 

1.403

0.977–2.017

 

PLR

  

0.107

  

0.101

  ≤ 164

Ref.

  

Ref.

  

 >164

1.342

0.939–1.918

 

1.361

0.942–1.968

 

SUVmax

  

< 0.001***

  

< 0.001***

  ≤ 11.6

Ref.

  

Ref.

  

 >11.6

2.400

1.674–3.440

 

2.976

2.024–4.375

 

LMR_SUV

  

< 0.001***

  

< 0.001***

 Score 0

Ref.

  

Ref.

  

 Score 1

2.228

1.383–3.590

0.001**

2.426

1.441–4.085

0.001**

 Score 2

4.449

2.719–7.281

< 0.001***

5.361

3.172–9.058

< 0.001***

  1. PFS progression-free survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, CR complete response, PR partial response, SD stable disease, PD progressive disease, CEA carcinoembryonic antigen, WBC white blood cell, LMR lymphocyte-monocyte ratio, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, SUVmax maximum standardized uptake value, HR hazard ratio, CI confidence intervals. *, p < 0.05; **, p < 0.01; ***, p < 0.001
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us